Sector News

MedTrace Pharma announces first subject scanned in the company’s RAPID-WATER-FLOW Phase 3 clinical trial

June 11, 2022
Life sciences

MedTrace Pharma A/S, a pharma and device company and an innovator in PET diagnostic imaging, announced today that it has scanned the first subject in its RAPID-WATER-FLOW Phase 3 clinical trial.

The global trial enrolls adults with suspected Coronary Artery Disease (CAD) and seeks to evaluate the use of 15O-water PET in diagnosing CAD.

The first subject scan took place at Aarhus University Hospital (AUH) in Denmark just two months after MedTrace received FDA approval of the company’s Investigational New Drug (IND) application and the approval to commence the trial.

Marcelo Di Carli, MD, Professor of Radiology and Medicine, at Brigham and Women’s Hospital and Harvard Medical School, is leading the trial as Principal Investigator.

– I am thrilled by the recruitment of the first subjects into the RAPID-WATER-FLOW study. This is a significant milestone for this exciting and important study and the first step towards bringing 15O-water as a clinical myocardial perfusion agent in the United States. The practical real-time production of 15O-water with MedTrace’s novel technology promises to revolutionize the practice of cardiac PET imaging by improving patient access to the most accurate approach to the non-invasive diagnosis of coronary artery disease, says Marcelo DiCarli.

15O-water at the point of care
MedTrace’s technology automatically produces and administers 15O-water to patients at the point of care. The automated software solution also provided by MedTrace (aQuant, in development) makes available a fully quantitative as well as visual 15O-water image analysis, including quantification of blood flow and segmental perfusion data, aiming to allow healthcare professionals to diagnose patients accurately and quickly.

The innovative solution allows for absolute blood flow imaging and quantification based upon the PET tracer 15O-water, which has long been acknowledged as the gold standard tracer for quantitative myocardial perfusion imaging.

Hospitals produce the radioactivity themselves on demand and are not dependent on third-party suppliers for radiopharmaceuticals.

Lars Christian Gormsen, Consultant, Professor at the Department of Nuclear Medicine & PET Center at AUH is the PI for the trial at AUH and is happy to be the first site to enroll a subject in this milestone study.

– Thanks to the excellent work by our colleagues at the Department of Cardiology and the staff at the department of Nuclear Medicine, the recruitment and subsequent examination of the first patient in the project progressed as planned. We are confident that this will also be the case in the remaining part of the project, says Lars Christian Gormsen.

At MedTrace the first subject enrolled is celebrated throughout the organization.

– I am beyond impressed with the dedication from the MedTrace clinical team and from our partners at AUH. They made it possible to reach this significant milestone in less than two months after we received the green light from the FDA. It shows that our company is moving at an incredible pace which is made possible by the talented and passionate people onboard, says Martin Stenfeldt, CEO of MedTrace.

The company is currently exploring clinical applications outside of cardiology and looking into research areas such as oncology and neurology. MedTrace’s clinical department will be growing significantly by the end of the year.

For more information on the 15O-water RAPID-WATER-FLOW clinical trial, visit: Radiolabeled Perfusion to Identify Coronary Artery Disease Using Water To Evaluate Responses of Myocardial Flow – Full-Text View – ClinicalTrials.gov

About the RAPID-WATER-FLOW Trials

The trial is a Phase 3, prospective, open-label, multicenter study of 15O-H2O injection for PET imaging of subjects with suspected CAD. 182 evaluable participants with suspected CAD will be included in the study at an estimated 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled in total to account for an estimated 15% drop-out rate. All participants will receive two doses of 15O-H2O as part of a single PET imaging session (one dose at rest and one during pharmacological stress with adenosine).

By MedTrace, Press Release

Source: medtrace.dk

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).